Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases
Gero today announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine-learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data.
As part of this research collaboration, the companies will leverage Pfizer’s expertise and Gero’s technology platform with the aim to identify genes and pathways linked to fibrotic diseases. Pfizer may advance the potential therapeutic targets and would be responsible for further preclinical and clinical development.
“Human data-driven drug discovery avoids the “preclinical trap” and has the potential to identify clinically relevant targets against human (not rodent) diseases. However, genetics-based target identification against age-related diseases is hindered by the irreversible component of human aging,” said Peter Fedichev, CEO of Gero. “Our technology platform allows us to separate irreversible effects of aging from reversible disease phenotypes to potentially identify the most actionable therapeutic targets.”
Gero will receive an upfront payment and is eligible to receive discovery milestone payments if the project progresses.
“We are excited to work with Pfizer, one of the world’s leading biopharmaceutical companies, to potentially identify targets against fibrotic diseases, which have a large unmet need,” said Alex Kadet, CBO of Gero. “We believe that combining our platform technology with Pfizer’s extensive disease expertise has the potential to identify high-value targets in this disease area.”
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more